The anti-tumor effect of fisetin is associated with the regulation of phosphoinositide-3-kinase (PI3K), protein kinase B (AKT), serine-threonine protein kinase (mTOR), and Wnt/β-catenin-driven pathways, as well as the activation of the tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL), leading to apoptosis and the inhibition of angiogenesis (downregulation of vascular endothelial growth factor (VEGF) expression). This evidence concerns the gene VEGFA and neoplasm.